The committee were aware of a clinical trial which was currently active and included people with HFpEF. The FAIR-HFpEF trial (https://clinicaltrials.gov/ct2/show/NCT03074591) will look at the outcomes exercise capacity, QoL, NYHA functional class, mortality and HF related hospitalisations in people with heart failure with preserved ejection fraction and iron deficiency with and without anaemia randomised to either IV iron or placebo. Based on this, the committee decided not to recommend further research in the area. Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 6.2.6 Pharmacological treatment for heart failure in people with heart failure and chronic kidney disease Chronic kidney disease (CKD), defined by a reduction in glomerular filtration rate (eGFR) to <60 and/or persistent albuminuria, is a common and important comorbidity in people with heart failure that confers significant additional risks of mortality, hospitalisation and adverse drug reactions. People with severe CKD (eGFR<30 ml/min/1.73 m2 ) have largely been excluded from key randomised controlled trials of heart failure pharmacotherapies, and the evidence base for such therapies in this important subgroup has therefore been lacking and clinical practice inconsistent The presence of even mild or moderate CKD (eGFR 31-59 ml/min/1.73 m2 ) can limit the ability to introduce and/or adequately up-titrate heart failure medications, many of which are potentially nephrotoxic and often reduced or discontinued in people with worsening renal function or acute kidney injury complicating intercurrent illness or concomitant drug therapy. 